Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis.

ABSTRACT:

Background

Nivolumab plus chemotherapy (NC) was recently approved as the first-line intervention for human epidermal growth factor receptor 2-negative advanced gastric/gastroesophageal junction cancer (GC/GEJC). Moreover, in the latest KEYNOTE-859 (NCT03675737), pembrolizumab plus chemotherapy (PC) was demonstrated to produce remarkable patient survival outcomes.

Objectives

The clinicians and patients need to assess NC and PC preference for cancer drugs.

Design

The cost-effective analysis.

Methods

In an economic assessment of the United States, United Kingdom, and Chinese healthcare systems using a Markov model simulated patients with GC/GEJC, two treatment decision branches with three health states and a tracked time horizon of 15 years were developed. The ove

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC10624011 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature